Nexium

(esomeprazole)

ApprovedSmall molecule

Esomeprazole reduces stomach acid to treat heartburn, acid reflux, and ulcers. It helps protect the stomach lining and allows it to heal.[2] Nexium is currently approved and in use across 47 indications[4].[1]

Nexium is one of 666 small molecule programs targeting Dyspepsia. It is currently in Approved.

Indications

296

Total Trials

Active Trials

665

Competitors

104

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

DyspepsiaCompleted

Cardiovascular DiseaseActive, not recruiting

AllergyCompleted

Chronic GastritisApproved

HemorrhageApproved

Non-Allergic RhinitisActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Laryngeal DiseaseApproved

StrictureWithdrawn

Gastric Mucosa-Associated Lymphoid Tissue LymphomaApproved

DyspepsiaApproved

Completed

Cardiovascular DiseaseApproved

Active, not recruiting

AllergyApproved

Completed

Chronic GastritisApproved

Approved

HemorrhageApproved

Approved

Non-Allergic RhinitisPreclinical

Active, not recruiting

Type 2 Diabetes MellitusPreclinical

Active, not recruiting

Laryngeal DiseaseApproved

Approved

StrictureApproved

Withdrawn

Gastric Mucosa-Associated Lymphoid Tissue LymphomaApproved

Approved

Showing 10 of 46 indications

Competition

Competitive Landscape

174 competitors in Schizophrenia

#DrugCompanyPhaseTrials

Nexium

DDexcel Pharma Technologies Ltd.

Approved

1 2

Ozempic

Novo Nordisk

Preclinical

1 3

Resotran

Takeda

Preclinical

1 4

Inapsine

Jazz Pharmaceuticals

Preclinical

1 5

Depakote

Ibrance

Lunesta

3 8

Luvox

SSolvay Pharmaceuticals

Preclinical

1 9

Catapres

Boehringer Ingelheim

Preclinical

1 10

Rapamune

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalNot yet recruiting

Healing

NCT07312370

Q3 2028

Post-ApprovalRecruiting

Peptic Ulcer

NCT05582174

Q4 2028

N/ARecruiting

Esophagitis

NCT06955520

Q2 2029

Phase 2Not yet recruiting

Bone Pain

NCT06903585

Clinical

Trials by Indication[1]

Gastroesophageal Reflux Disease16 trials

Symptomatic Gastroesophageal Reflux Disease: Double Blind Randomized Controlled Study of On-demand Therapy Versus Maintenance Therapy

Completed·—·Phase 3·NCT00164840·244 enrolled

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy Study Comparing 4 Weeks of Treatment With Esomeprazole 20 mg qd and 40 mg qd to Placebo qd in Patients With Heartburn and Sleep Disturbances Associated With Gastroesophageal Reflux Disease (GERD)

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00628342·600 enrolled

An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00629564·60 enrolled

Show 13 more trials

Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Completed· Eisai logo

Eisai·Phase 3·NCT00658775·1,069 enrolled

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)

Completed· Eisai logo

Eisai·Phase 3·NCT00658632·1,397 enrolled

An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD)

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00242736·350 enrolled

Heartburn, Gastroesophageal Reflux Disease

Recruiting·IIncheon St.Mary's Hospital·Phase 4·NCT07268820·160 enrolled

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 2, Therapeutic Exploratory Study)

Completed· Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.·Phase 2·NCT03184324·211 enrolled

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Completed· Eisai logo

Eisai·Phase 3·NCT00658528·1,061 enrolled

Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00625495·60 enrolled

The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis

Completed·MMayo Clinic·Phase 2/3·NCT00728481·51 enrolled

Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients

Completed·LLivzon Pharmaceutical Group Inc.·Phase 3·NCT02860624·550 enrolled

Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients

Unknown status·LLivzon Pharmaceutical Group Inc.·Phase 2·NCT01107938·330 enrolled

Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease

Completed·OOnconic Therapeutics Inc.·Phase 2·NCT04282954·188 enrolled

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)

Completed· Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.·Phase 3·NCT03736369·263 enrolled

Gastroesophageal Reflux Disease (GERD)/Nighttime Heartburn and Driving Performance

Completed·—·N/A·NCT01079884·18 enrolled

Helicobacter Pylori11 trials

High Dose of Dual Therapy Plus Bismuth for Helicobacter Pylori Treatment

Completed·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT03405584·160 enrolled

Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients

Completed·UUniversity of Zurich·Phase 4·NCT00574925

Evaluation of Saccharomyces Boulardii Combined With Standard Quadruple Therapy for Eradication of Helicobacter Pylori

Completed·HHuazhong University of Science and Technology·N/A·NCT03688828·360 enrolled

Show 8 more trials

The Effect of Broccoli Sprout Extract and Probiotics for Eradication of Helicobacter Pylori

Unknown status·KKyunghee University Medical Center·Phase 4·NCT03220542·360 enrolled

A Study of Vonoprazan in Adults With Helicobacter Pylori

Completed· Takeda logo

Takeda·Phase 1·NCT04753437·44 enrolled

Doxycycline for Helicobacter Pylori Rescue Treatment

Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT05874570·368 enrolled

High Dose of Amoxicillin and Metronidazole Plus Bismuth For Helicobacter Pylori Treatment

Completed·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT03557437·216 enrolled

The Evaluation of Triple Therapy With Vonoprazan, Amoxicillin and Bismuth for Eradication of Helicobacter Pylori

Unknown status·HHuazhong University of Science and Technology·N/A·NCT05189444·672 enrolled

Keverprazan Combined with Amoxicillin for the Treatment of Helicobacter Pylori

Not yet recruiting·KKey Laboratory for Gastrointestinal Diseases of Gansu Province·N/A·NCT06851468·264 enrolled

Effect of Vitamin D on Drug Resistant Helicobacter Pylori (HP) Eradication Study

Unknown status·—·Phase 3·NCT03142620·96 enrolled

Effectiveness of Rifabutin for Treatment of Helicobacter Pylori

Unknown status·RRabin Medical Center·Phase 3·NCT04652284·300 enrolled

Esophagitis11 trials

Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

Completed·HHK inno.N Corporation·Phase 2·NCT02028663·206 enrolled

A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00641602·1,000 enrolled

Indonesian Study of Vonoprazan Vs Esomeprazole in Erosive Esophagitis

Not yet recruiting·IIndonesia University·Phase 4·NCT06720610·216 enrolled

Show 8 more trials

Reflux Esophagitis Phase III Study (Initial Treatment)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00633932·602 enrolled

Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT01669811·1,398 enrolled

Efficacy and Safety of LXI-15028 Comparing With Esomeprazole in the Treatment of Erosive Esophagitis

Completed·SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.·Phase 3·NCT03615677·261 enrolled

Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy

Completed·—·Phase 4·NCT01874535·408 enrolled

Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis

Completed·YYuhan Corporation·Phase 2·NCT01538849·154 enrolled

JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis

Completed·OOnconic Therapeutics Inc.·Phase 3·NCT05443984·300 enrolled

Vonaprazan Versus Esomeprazole for Healing of LA Grade B or Higher Esophagitis After POEM

Recruiting·—·N/A·NCT06955520·300 enrolled

Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

Completed·HHK inno.N Corporation·Phase 3·NCT03006874·302 enrolled

Oral8 trials

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Male Volunteers

Completed· Daewoong Pharmaceutical Co. LTD. logo

Daewoong Pharmaceutical Co. LTD.·Phase 1·NCT02757144·120 enrolled

A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants

Completed· Incyte logo

Incyte·Phase 1·NCT07018635·63 enrolled

Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)

Completed· Takeda logo

Takeda·Phase 3·NCT02037477·20 enrolled

Show 5 more trials

A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.

Completed· Roche logo

Roche·Phase 1·NCT02023125·42 enrolled

Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil

Completed· United Therapeutics logo

United Therapeutics·Phase 1·NCT00963027·30 enrolled

Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH4808 After Oral Administration in Healthy Male Subjects

Completed·YYuhan Corporation·Phase 1·NCT01007019·134 enrolled

Safety, Tolerability, PK, PD of Escalating Single and Multiple Oral Doses of CJ-12420 in Healthy Male Subjects

Completed·HHK inno.N Corporation·Phase 1·NCT01473173·59 enrolled

A Study to Evaluate the Bioequivalence of Single Oral Dose of Esomeprazole Capsule and Tablet Formulation in Healthy Participants

Completed· Takeda logo

Takeda·Phase 1·NCT03083639·52 enrolled

Helicobacter Pylori Eradication7 trials

Vonoprazan for Helicobacter Pylori Eradication in Adolescents

Completed·—·Phase 3·NCT06162949·242 enrolled

Efficacy and Safety of Vonoprazan as First-line Treatment for Helicobacter Pylori Eradication

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT04907747·234 enrolled

Helicobacter Pylori Eradication With Probiotics Combined With Triple Therapy Versus Bismuth-containing Quadruple Therapy

Completed·XXijing Hospital of Digestive Diseases·Phase 4·NCT05237115·600 enrolled

Show 4 more trials

Levofloxacin-Doxycycline for Helicobacter Pylori Eradication in Saudi Arabia

Completed·KKing Faisal Specialist Hospital & Research Center·N/A·NCT02884713·55 enrolled

Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology

Completed·XXijing Hospital of Digestive Diseases·Phase 4·NCT05742568·124 enrolled

Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy

Completed·XXijing Hospital of Digestive Diseases·Phase 4·NCT02296021·612 enrolled

Comparison of the Efficacies of Two Novel Dose Dual Therapies in the First-line Helicobacter Pylori Eradication

Unknown status·—·Phase 3·NCT06811207·300 enrolled

71 more indications

Adult7 trials

A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult Participants

Completed·CCerevel Therapeutics, LLC·Phase 1·NCT06366243·20 enrolled

A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT06181084·60 enrolled

Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01358383·28 enrolled

Show 4 more trials

A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults

Completed· Bayer logo

Bayer·Phase 1·NCT05061563·14 enrolled

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participant

Completed· Incyte logo

Incyte·Phase 1·NCT06213818·137 enrolled

A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy

Completed·TTheriva Biologics, Inc.·Phase 1/2·NCT02473640·15 enrolled

Bioequivalence Study of Esomeprazole 20 Milligram (mg) Delayed-Release Capsules in Healthy Adult Participants

Completed·HHALEON·Phase 1·NCT05265247·61 enrolled

Peptic ulcer6 trials

The Efficacy of Double Doses of Oral Esomeprazole in Preventing Rebleeding for Patients With Bleeding Peptic Ulcers

Completed·NNational Cheng-Kung University Hospital·Phase 4·NCT01591083·474 enrolled

PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers

Recruiting·—·Phase 4·NCT05582174·594 enrolled

Oral vs Intravenous and Proton Pump Inhibitor (PPI）for Peptic Ulcer Bleeding (PUB)

Withdrawn·—·Phase 4·NCT01123031

Show 3 more trials

Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer

Completed·KKaohsiung Veterans General Hospital.·Phase 2·NCT01138969·165 enrolled

Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00441727·2,426 enrolled

Long-term Oral Esomeprazole for Prevention of Peptic Ulcer Rebleeding in High-risk Patients

Completed·HHsiu-Chi Cheng·Phase 4·NCT02456012·268 enrolled

Efficacy and Safety6 trials

Study to Evaluate the Efficacy and Safety of Tegoprazan in ERD Patients With Nighttime Heartburn and Sleep Disturbance

Completed·HHK inno.N Corporation·Phase 4·NCT04309916·46 enrolled

Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD)

Terminated· Pfizer logo

Pfizer·Phase 2·NCT00730665·81 enrolled

A Study to Evaluate the Efficacy and Safety of Tegoprazan in GERD Patients With Nighttime Heartburn

Unknown status·HHK inno.N Corporation·Phase 4·NCT05701540·338 enrolled

Show 3 more trials

Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication

Completed·XXijing Hospital of Digestive Diseases·Phase 4·NCT06514274·558 enrolled

Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment

Active, not recruiting·XXijing Hospital of Digestive Diseases·Phase 4·NCT06523764·208 enrolled

A Multi-center, Double-blinding, Parallel and Positive-controlled Phase III Clinical Trial for Efficacy and Safety Evaluation of Ilaprazole Sodium for Injection on Prevention of Stress Ulcer Bleeding

Completed·LLivzon Pharmaceutical Group Inc.·Phase 3·NCT05841394·449 enrolled

Helicobacter Pylori Infection6 trials

Comparison Between High-dose Amoxicillin Dual Therapy and Pylera Quadruple Therapy in the Treatment of Helicobacter Pylori Infection

Unknown status·UUnidade Local de Saúde do Alto Ave, EPE·Phase 1·NCT05100446·100 enrolled

Recurrence Rate Comparison Between Esomeprazole and Lansoprazole in Eradicating Helicobacter Pylori Infection Among Children

Completed·FFinni Kollins·Phase 2/3·NCT05861687·51 enrolled

A RCT of the Efficacy of Vonoprazan 20mg QD in the Treatment of Helicobacter Pylori Infection

Unknown status·FFirst People's Hospital of Hangzhou·Phase 4·NCT05590286·100 enrolled

Show 3 more trials

Comparison of Two Dual Therapies in the First-line Treatment of Helicobacter Pylori Infection （SHARE2301）

Unknown status·YYanqing Li·N/A·NCT05870683·368 enrolled

Esomeprazole, Moxifloxacin and Amoxicilin for Rescue Therapy of Helicobacter Pylori Infection

Unknown status·TTechnische Universität Dresden·Phase 3·NCT00455806·132 enrolled

A Study to Evaluate the Efficacy and Safety of Bismuth-Containing Quadruple Therapy With Oral Vonoprazan (TAK-438) 20 mg Compared to Esomeprazole 20 mg Twice Daily in Paticipants With Helicobacter Pylori Infection

Completed· Takeda logo

Takeda·Phase 3·NCT04198363·510 enrolled

Interaction5 trials

Drug Drug Interaction Study Of Crizotinib With Esomeprazole.

Completed· Pfizer logo

Pfizer·Phase 1·NCT01549574·16 enrolled

Drug-drug Interaction Between Aceclofenac 200 mg and Esomeprazole 20 mg in Healthy Male Volunteers

Unknown status·DDong Wha Pharmaceutical Co. Ltd.·Phase 1·NCT03127046·30 enrolled

Drug Interaction Study Between AZD3355 and Nexium

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00684190·30 enrolled

Show 2 more trials

Study to Evaluate the Interaction Between Aspirin and Nexium

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01199328·34 enrolled

Drug-Drug Interaction Study of Esomeprazole (D961H) Capsule and Loxoprofen Tablet After Repeated Oral Administration in Japanese Males

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00676117·30 enrolled

Dyspepsia5 trials

Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia

Unknown status·UUniversity of Malaya·Phase 4·NCT02134405·200 enrolled

Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia

Unknown status·RRuttonjee Hospital·Phase 4·NCT00978159·128 enrolled

Proton Pump Inhibitors Effects on Dyspepsia During Ramadan Fasting

Completed·UUniversity of Monastir·Phase 1/2·NCT05287633·500 enrolled

Show 2 more trials

Nexium Dyspepsia/AST

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00251914·1,500 enrolled

BRAVO Study for Functional Dyspepsia

Completed·—·Phase 4·NCT01349413·130 enrolled

GERD4 trials

Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)

Completed· Takeda logo

Takeda·Phase 2·NCT02743949·256 enrolled

Study Using Esomeprazole as a Diagnostic Test for GERD in Patients With NCCP

Completed·NNational University Hospital, Singapore·N/A·NCT00786695·60 enrolled

Symptom Adapted Therapy in GERD Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00343161·441 enrolled

Show 1 more trial

Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00444275·3,029 enrolled

Tics4 trials

A Study to Investigate the Effect of Esomeprazole and the Effect of Food on the Pharmacokinetics of Balovaptan in Healthy Volunteers

Completed· Roche logo

Roche·Phase 1·NCT04156646·16 enrolled

A Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of Isavuconazole

Completed· Astellas logo

Astellas·Phase 1·NCT02128893·24 enrolled

Study to Evaluate the Influence of Tegoprazan on the Pharmacokinetics of Proguanil in Healthy Volunteers

Completed·SSeoul National University Hospital·Phase 1·NCT04568772·19 enrolled

Show 1 more trial

Study to Evaluate Effects of Food or Proton Pump Inhibitor on the Pharmacokinetics of Itraconazole in Healthy Volunteers

Completed·SSeoul National University Hospital·Phase 1·NCT04942652·13 enrolled

Preeclampsia4 trials

Metformin and Esomeprazole in Preterm Pre-eclampsia

Terminated·CChristiana Care Health Services·Phase 4·NCT06359015·4 enrolled

Esomeprazole for the Prevention of Preeclampsia

Unknown status·—·Phase 3·NCT03717740·1,000 enrolled

Metformin and Esomeprazole For Preterm Pre-eclampsia

Unknown status·CChristiana Care Health Services·Phase 1·NCT05232994·38 enrolled

Show 1 more trial

Esomeprazole in Treatment of Early Onset Preeclampsia (ESOPE Trial)

Completed·—·Phase 2/3·NCT03213639·205 enrolled

MPA3 trials

Study Comparing a Fixed-Dose Capsule of Esomeprazole 40mg and LDA 325mg With Free Combination

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00688428·84 enrolled

A Study in Healthy People to Compare Two Different Tablets of BI 685509 and to Test How Food and Esomeprazole Influence the Amount of BI 685509 in the Blood

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT06193811·16 enrolled

A Study to Compare PK, PD and Safety of the AD-206 and Esomeprazole

Completed·AAddpharma Inc.·Phase 1·NCT03980756·88 enrolled

Helicobacter3 trials

Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy

Completed·YYongquan Shi·Phase 4·NCT06168084·688 enrolled

Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy

Completed·XXijing Hospital of Digestive Diseases·Phase 4·NCT04678492·658 enrolled

Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy

Completed·XXijing Hospital of Digestive Diseases·Phase 4·NCT03609892·658 enrolled

Treatment3 trials

Proton Pump Inhibitor Treatment Stop

Completed·OOdense University Hospital·Phase 4·NCT00120315·171 enrolled

On Demand Treatment of Reflux Disease

Completed·NNorwegian University of Science and Technology·Phase 4·NCT00184522·82 enrolled

Open, Randomised, Multi-center Study of on Demand Versus Continuous Esomeprazole Treatment in Patient With GERD

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02670642·877 enrolled

Prevention3 trials

AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers

Completed· AbbVie logo

AbbVie·Phase 1·NCT00325715·150 enrolled

PPI for Prevention of Post-sphincterotomy Bleeding

Completed·TThe University of Hong Kong·Phase 3·NCT01873079·185 enrolled

Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00595517·395 enrolled

Gastrointestinal3 trials

Esomeprazole for Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00241553·276 enrolled

Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00241527·556 enrolled

Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00241540·808 enrolled

Gastric Ulcer3 trials

Efficacy and Safety Study of Esomeprazole 20mg qd vs Ranitidine 150mg Bid in Patients With an NSAID-induced Gastric Ulcer

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00401752·397 enrolled

Prevention of Gastric Ulcers

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00629512·504 enrolled

A Comparative Efficacy and Safety Study of Nexium Delayed-Release Capsules (40mg qd and 20mg qd) Versus Ranitidine 150mg Bid for the Healing of NSAID-Associated Gastric Ulcers When Daily NSAID Use is Continued in Subjects in the US Only

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00633412·400 enrolled

Intravenous3 trials

Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT02157376·343 enrolled

Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00635414·60 enrolled

A Comparison of Gastric pH Control With High Dose Intravenous or Oral Esomeprazole

Terminated·—·Phase 2·NCT00164788·7 enrolled

Clopidogrel3 trials

Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT01147588·149 enrolled

Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Subjects

Unknown status·HHK inno.N Corporation·Phase 1·NCT06164834·48 enrolled

Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Male Participants

Completed·HHK inno.N Corporation·Phase 1·NCT03814642·25 enrolled

Gastro-oesophageal Reflux Disease2 trials

A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 4·NCT00464308·1,392 enrolled

The Use of Proton Pump Inhibitor for the Treatment of Non-erosive Gastro-oesophageal Reflux Disease in Chinese Population

Unknown status·HHospital Authority, Hong Kong·N/A·NCT00516971·200 enrolled

Eosinophilic Esophagitis2 trials

Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis

Completed·WWalter Reed Army Medical Center·N/A·NCT00895817·42 enrolled

Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis

Completed·UUniversity of Utah·Phase 2·NCT00123656·30 enrolled

AIN2 trials

Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy

Unknown status·SSir Run Run Shaw Hospital·Phase 4·NCT02894268·300 enrolled

Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori

Completed·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT01667575·180 enrolled

Gastric2 trials

Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00206050·40 enrolled

Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00410592·90 enrolled

Gastric Acid2 trials

Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients

Completed·UUniversity of Kansas Medical Center·Phase 2·NCT00222131·73 enrolled

The Effect of Protein on Calcium Absorption and Gastric Acid Production

Completed·YYale University·Phase 4·NCT00719160·12 enrolled

ESS2 trials

A Double Blind Study Comparing Two Doses of IV Esomeprazole After Successful Endoscopic Therapy

Unknown status·TTaipei Medical University·Phase 4·NCT01275937·65 enrolled

A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant

Completed· Pfizer logo

Pfizer·Phase 1·NCT06275841·12 enrolled

H Pylori Infection2 trials

Feasibility Study of the Proposed Test-and-treat Screening Program in Younger Participants With H. Pylori Infection

Unknown status·NNational Institute of Public Health, Slovenia··NCT06216639·2,000 enrolled

Genotypic Resistance Guided Therapy for Refractory H. Pylori Infection

Unknown status·NNational Taiwan University Hospital·Phase 4·NCT03555526·320 enrolled

First-line Treatment2 trials

10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection

Completed·EElpen Pharmaceutical Co. Inc.·Phase 4·NCT02959255·364 enrolled

Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment of Different Tetracycline Doses

Completed·SShandong University·Phase 4·NCT05431075·406 enrolled

ART2 trials

A Multiple Dose Study of LY3502970 in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT05051566·26 enrolled

A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04468815·24 enrolled

Bismuth Quadruple Therapy2 trials

Vonoprazan-containing Triple Therapy Versus Empiric Bismuth Quadruple Therapy for First-line Helicobacter Pylori Treatment: a Randomized Clinical Trial

Unknown status·SShanghai East Hospital·Phase 4·NCT05726734·100 enrolled

Study on the Efficacy and Safety of Berberine, Minocycline, Esomeprazole, and Colloidal Bismuth Quadruple Therapy in the Initial Treatment of Helicobacter Pylori.

Unknown status·XXijing Hospital of Digestive Diseases·Phase 4·NCT06603688·548 enrolled

Randomized2 trials

Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00626262·60 enrolled

A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00625274·100 enrolled

Double-blind2 trials

Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00644735·750 enrolled

Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms

Completed·VVecta Ltd.·Phase 2·NCT01059383·52 enrolled

Second-line Treatment2 trials

Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy

Completed·SSeoul National University Bundang Hospital·Phase 4·NCT01792700·648 enrolled

Sequential Versus Quadruple Therapy in the Second-line Treatment

Unknown status·NNational Taiwan University Hospital·Phase 4·NCT03208426·240 enrolled

Barrett's esophagus2 trials

On-demand PPI Therapy is Effective on Controlling Symptoms in Patients With Barrett's Esophagus.

Completed·KKaohsiung Veterans General Hospital.·N/A·NCT04329000·218 enrolled

An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00352261·80 enrolled

Chest pain1 trial

Chest Pain Pilot Study

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00251901·600 enrolled

Surgery1 trial

Esomeprazole (NEXIUM) vs. Surgery

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00251927·626 enrolled

Heart Disease1 trial

Prevention of Gastrointestinal Bleeding in Patients With Severe Ischemic Heart Disease

Completed·RRuttonjee Hospital·Phase 4·NCT00683111·500 enrolled

Renal Transplantation1 trial

Esomeprazole or Pantoprazole in Renal Transplantation

Completed·FFuture University in Egypt·N/A·NCT03812419·47 enrolled

Medication1 trial

Study Comparing Esomeprazole and ASA Combined Together as One Capsule Versus These Medications Taken Separately

Terminated· AstraZeneca logo

AstraZeneca·Phase 1·NCT01015729·30 enrolled

Reflux Episodes1 trial

Twenty-Four Hour Combined Multi-Channel Impedance and pH Ambulatory Monitoring: Impedance Reflux Episodes of Patients On and Off Proton Pump Inhibitor Therapy

Completed·WWalter Reed National Military Medical Center·N/A·NCT01710800·41 enrolled

Critically Ill Patients1 trial

Gastric pH in Critically Ill Patients

Completed·MMedical University of Vienna·Phase 4·NCT00590928·75 enrolled

Acid Reflux1 trial

Effect of Esomeprazole 40 mg.Daily for 7 Days on Acid Reflux and Related Arousals During Sleep in Patients With GERD

Unknown status·SSouthern Arizona VA Health Care System·Phase 2/3·NCT01089959·20 enrolled

Prospective1 trial

Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study

Completed·MMidwest Biomedical Research Foundation·N/A·NCT02081404·98 enrolled

Non-Alcoholic Steatohepatitis1 trial

Clinical Study Evaluating the Safety and Efficacy of Esomeprazole in Treatment of Non-alcoholic Steatohepatitis

Recruiting·SSadat City University·Phase 1/2·NCT06302049·46 enrolled

SLE1 trial

The ESG Integrity Study: Effect of Proton Pump Inhibitors on the Structural Integrity of Endoscopic Sleeve Gastroplasty

Recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 4·NCT06283381·40 enrolled

Peptic Ulcer Disease1 trial

Intravenous Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease

Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT04432233·60 enrolled

Granuloma1 trial

Effect of Acid Suppression With Esomeprazole on Vocal Cord Granulomas

Withdrawn·VVanderbilt University·Phase 3·NCT00567658

Allergy1 trial

Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy

Completed·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT03708848·112 enrolled

MPR1 trial

Esomeprazole in PPI Failures - IMPROVE

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00272701·450 enrolled

Homeostasis1 trial

Effect of Dexlansoprazole on Bone Homeostasis

Completed· Takeda logo

Takeda·Phase 1·NCT01216293·115 enrolled

Stricture1 trial

Study of Proton Pump Inhibitors (PPI) to Prevent Strictures After Gastric Bypass Surgery

Withdrawn·WWeill Medical College of Cornell University·Phase 4·NCT00361985

Upper Gastrointestinal Bleeding1 trial

The Use of Hexacapron in Upper Gastrointestinal Bleeding

Unknown status·SShaare Zedek Medical Center·N/A·NCT02071316·300 enrolled

Sleep Disturbance1 trial

Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances

Unknown status·—·Phase 4·NCT02277886·340 enrolled

Thyroid Associated Ophthalmopathy1 trial

The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy

Completed·MMedical University of Vienna·Phase 3·NCT01579539·18 enrolled

Chronic Gastritis1 trial

Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT01119768·305 enrolled

Pneumonia1 trial

Proton Pump Inhibitors and Risk of Community-acquired Pneumonia

Completed·CCanadian Network for Observational Drug Effect Studies, CNODES··NCT02555852·4,238,504 enrolled

Outcome1 trial

Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00392002·2,000 enrolled

Drug Interactions1 trial

Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects

Completed·BBridge Biotherapeutics, Inc.·Phase 1·NCT04138836·48 enrolled

Bariatric Surgery1 trial

Use Of Esomeprazole In Postoperative Bariatric Surgery Patients Users And Non-Users Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00608712·140 enrolled

Sepsis1 trial

Esomeprazole to Reduce Organ Failure in Sepsis

Completed·UUniversità Vita-Salute San Raffaele·Phase 3·NCT03452865·300 enrolled

Gastritis1 trial

A RCT of Triple Therapy With Proton Pump Inhibitor vs Vonoprazan for Helicobacter Pylori Gastritis

Unknown status·—·Phase 4·NCT03908619·252 enrolled

Bone pain1 trial

Non Steroidal Anti-inflammatory Drugs in the Prevention of Bone Pain Flares After Palliative Radiotherapy

Not yet recruiting·—·Phase 2·NCT06903585·385 enrolled

Phase 11 trial

A Phase 1 Study of Tegoprazan on Healthy Male Volunteers

Unknown status·HHK inno.N Corporation·Phase 1·NCT03530228·44 enrolled

Resistance1 trial

Genotypic Resistance-guided Versus Empirical Therapy for H. Pylori Eradication.

Unknown status·—·Phase 4·NCT04090021·304 enrolled

Adolescent1 trial

Safety of Daily Dose Esomeprazole for GERD for Pediatric and Adolescent Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00241501·140 enrolled

Head and Neck Cancer1 trial

Evaluation of Esomeprazole in Treating Gastro-esophageal Reflux Disease (GERD) in Head and Neck Cancer Patients Exposed to Radiation Therapy

Terminated·DDouglas Trask·N/A·NCT00222079·40 enrolled

Reflux1 trial

vMII for Measurement of Oesophageal Bolus Transport and Reflux

Terminated·GGuy's and St Thomas' NHS Foundation Trust·N/A·NCT00604942·140 enrolled

Gastric Emptying1 trial

Esomeprazole and Gastric Emptying of Beer

Completed·HHeidelberg University·Phase 4·NCT00472550·16 enrolled

Total Knee Arthroplasty1 trial

The Effect of Prolonged Multimodal Analgesic Regimen on Post Hospital Discharge Opioid Use and Pain Control After Primary Total Knee Arthroplasty

Completed·RRothman Institute Orthopaedics·N/A·NCT04003350·216 enrolled

Pilot Study1 trial

Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment

Completed· Pfizer logo

Pfizer·Phase 4·NCT02708355·55 enrolled

Healing1 trial

Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing

Not yet recruiting·LLanZhou University·Phase 4·NCT07312370·120 enrolled

Side Effects1 trial

The Effects of Nexium on the Side Effects Associated With a Colonoscopy Prep

Completed·TThomas Jefferson University·Phase 4·NCT00225238·500 enrolled

Intensive Care Unit1 trial

Comparison of Esomeprazole and Famotidine for Stress Ulcer Prophylaxis in Neurosurgical Intensive Care Unit

Completed·FFar Eastern Memorial Hospital·Phase 4·NCT00633035·60 enrolled

Unspecified9 trials

PPI Sequencing Study

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00384592·100 enrolled

PPI Test in GP Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 4·NCT00318084·100 enrolled

A Study in Healthy Men to Test Whether Esomeprazole Influences the Amount of BI 3000202 in the Blood

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT06419660·15 enrolled

Show 6 more trials

A Study of IBI351 in Healthy Subjects

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT05688124·24 enrolled

Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations

Completed·—·Phase 2·NCT01983774·21 enrolled

ASTERIX: Low Dose ASA and Nexium

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00251966·960 enrolled

In Vivo Quantification of Dental Demineralisation Using OCT With and Without Esomeprazole

Completed·BBrain-Gut Research Group·Phase 1/2·NCT00564330·30 enrolled

The Need of Revisiting to an Outpatient Clinic After the Prescription of Vonoprazan or Esomeprazole

Completed·SShowa Inan General Hospital·N/A·NCT04720781·300 enrolled

13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors)

Completed·MMeridian Bioscience, Inc.·Phase 4·NCT00825630·123 enrolled

Regulatory

FDA Approval Timeline[5]

Feb 20, 2001

NEXIUM

NDA NDA021153

Feb 20, 2001

NEXIUM

NDA NDA021153

May 16, 2001

NEXIUM

NDA NDA021153

Mar 14, 2002

NEXIUM

NDA NDA021153

Sep 20, 2002

NEXIUM

NDA NDA021153

Oct 1, 2002

NEXIUM

NDA NDA021153

Feb 27, 2003

NEXIUM

NDA NDA021153

Jan 9, 2004

NEXIUM

NDA NDA021153

Apr 23, 2004

NEXIUM

NDA NDA021153

Nov 24, 2004

NEXIUM

NDA NDA021153

Mar 31, 2005

NEXIUM IV

NDA NDA021689

Jun 6, 2005

NEXIUM

NDA NDA021153

Feb 16, 2006

NEXIUM

NDA NDA021153

Apr 28, 2006

NEXIUM

NDA NDA021153

Sep 15, 2006

NEXIUM

NDA NDA021153

Sep 26, 2006

NEXIUM

NDA NDA021153

Oct 11, 2006

NEXIUM

NDA NDA021153

Apr 27, 2007

NEXIUM

NDA NDA021153

Apr 27, 2007

NEXIUM

NDA NDA021153

Jan 11, 2008

NEXIUM

NDA NDA021153

Jan 11, 2008

NEXIUM

NDA NDA021957

Feb 27, 2008

NEXIUM

NDA NDA022101

Jan 15, 2009

NEXIUM

NDA NDA022101

Jan 15, 2009

NEXIUM

NDA NDA021957

Jan 15, 2009

NEXIUM

NDA NDA021153

Jun 18, 2009

NEXIUM

NDA NDA021957

Oct 9, 2009

NEXIUM

NDA NDA022101

Oct 9, 2009

NEXIUM

NDA NDA021153

Mar 4, 2010

NEXIUM

NDA NDA021153

Mar 4, 2010

NEXIUM

NDA NDA021957

Mar 4, 2010

NEXIUM

NDA NDA022101

Sep 3, 2010

NEXIUM

NDA NDA022101

Sep 3, 2010

NEXIUM

NDA NDA021957

Sep 3, 2010

NEXIUM

NDA NDA021153

Jun 21, 2011

NEXIUM

NDA NDA021957

Jun 21, 2011

NEXIUM

NDA NDA021153

Jun 21, 2011

NEXIUM

NDA NDA022101

Jun 30, 2011

NEXIUM

NDA NDA021153

Jun 30, 2011

NEXIUM

NDA NDA022101

Jun 30, 2011

NEXIUM

NDA NDA021957

Dec 15, 2011

NEXIUM

NDA NDA021957

Dec 15, 2011

NEXIUM

NDA NDA021957

Jan 20, 2012

NEXIUM

NDA NDA021153

Jan 20, 2012

NEXIUM

NDA NDA022101

Jan 20, 2012

NEXIUM

NDA NDA021957

Sep 28, 2012

NEXIUM

NDA NDA021153

Sep 28, 2012

NEXIUM

NDA NDA022101

Sep 28, 2012

NEXIUM

NDA NDA021957

Oct 9, 2012

NEXIUM

NDA NDA022101

Oct 9, 2012

NEXIUM

NDA NDA021957

Oct 9, 2012

NEXIUM

NDA NDA021153

Nov 28, 2012

NEXIUM

NDA NDA022101

Nov 28, 2012

NEXIUM

NDA NDA021957

Nov 28, 2012

NEXIUM

NDA NDA021153

Jun 17, 2013

NEXIUM

NDA NDA021153

Oct 4, 2013

NEXIUM

NDA NDA021153

Feb 14, 2014

NEXIUM

NDA NDA021153

Feb 25, 2014

NEXIUM

NDA NDA022101

Feb 25, 2014

NEXIUM

NDA NDA021153

Feb 25, 2014

NEXIUM

NDA NDA021957

Mar 27, 2014

NEXIUM

NDA NDA022101

Mar 27, 2014

NEXIUM

NDA NDA021957

Mar 27, 2014

NEXIUM

NDA NDA021153

Mar 28, 2014

NEXIUM 24HR

NDA NDA204655

Oct 3, 2014

NEXIUM 24HR

NDA NDA204655

Dec 19, 2014

NEXIUM

NDA NDA021957

Dec 19, 2014

NEXIUM

NDA NDA022101

Dec 19, 2014

NEXIUM

NDA NDA021153

Jun 2, 2015

NEXIUM 24HR

NDA NDA204655

Jun 23, 2015

NEXIUM 24HR

NDA NDA204655

Nov 23, 2015

NEXIUM 24HR

NDA NDA207920

Jun 17, 2016

NEXIUM 24HR

NDA NDA204655

Oct 24, 2016

NEXIUM

NDA NDA021957

Oct 24, 2016

NEXIUM

NDA NDA022101

Oct 24, 2016

NEXIUM

NDA NDA021153

Dec 20, 2016

NEXIUM

NDA NDA021153

Dec 20, 2016

NEXIUM

NDA NDA022101

Dec 20, 2016

NEXIUM

NDA NDA021957

Jan 9, 2017

NEXIUM 24HR

NDA NDA204655

Feb 3, 2017

NEXIUM 24HR

NDA NDA204655

Feb 3, 2017

NEXIUM 24HR

NDA NDA207920

Dec 18, 2017

NEXIUM 24HR

NDA NDA207920

Jan 24, 2018

NEXIUM 24HR

NDA NDA204655

Jun 7, 2018

NEXIUM

NDA NDA021153

Jun 7, 2018

NEXIUM

NDA NDA021957

Jun 7, 2018

NEXIUM

NDA NDA022101

Apr 4, 2019

NEXIUM 24HR

NDA NDA204655

Apr 4, 2019

NEXIUM 24HR

NDA NDA207920

Oct 20, 2020

ESOMEPRAZOLE MAGNESIUM

NDA NDA214278

Nov 27, 2020

NEXIUM

NDA NDA021957

Nov 27, 2020

NEXIUM

NDA NDA021153

Nov 27, 2020

NEXIUM

NDA NDA022101

Dec 4, 2020

NEXIUM 24HR

NDA NDA204655

Aug 25, 2021

NEXIUM

NDA NDA021153

Aug 25, 2021

NEXIUM

NDA NDA021957

Aug 25, 2021

NEXIUM

NDA NDA022101

Mar 4, 2022

NEXIUM

NDA NDA021957

Mar 4, 2022

NEXIUM

NDA NDA022101

Mar 4, 2022

NEXIUM

NDA NDA021153

Sep 6, 2022

NEXIUM 24HR

NDA NDA204655

Sep 6, 2022

NEXIUM 24HR

NDA NDA207920

Jul 18, 2023

NEXIUM

NDA NDA021153

Jul 18, 2023

NEXIUM

NDA NDA021957

Jul 18, 2023

NEXIUM

NDA NDA022101

Sources

References

[1]
ClinicalTrials.gov — 296 trial records for esomeprazole. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Nexium drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — esomeprazole compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for esomeprazole. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021153). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Nexium. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Dexcel Pharma Technologies Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Potassium-Transporting Atpase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: DDexcel Pharma Technologies Ltd.

Patent Landscape[6]

Patent Cliff

Dec 8, 2036

Earliest patent expiration — generic entry possible after this date

Patent #Expires

10076494Dec 8, 2036